FDA grants fast track status to Achillion ACH-1625 drug
ACH-1625, a once-daily HCV protease inhibitor and an open chain, non-covalent NS3 protease inhibitor, is currently being evaluated in a Phase 2 clinical trial as a treatment for
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The company will also adopt Cegedim Relationship Management’s OneKey, the global healthcare professional (HCP) database, and insightful Mobile Intelligence Analytics. Pharmaceutical CRM Solution is believed to deliver Operational